Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
0 hedge funds and large institutions have $0 invested in Adamas Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 62 closing their positions.
100% less funds holding
Funds holding: 63 → 0 (-63)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $148M → $0 (-$148M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 62
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.8M |
| 2 |
AC
Armistice Capital
New York
|
-$19.6M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$19.2M |
| 4 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$12.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.67M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Capstone Investment Advisors
New York
| – | -$50K | -10,123 | Closed |
|
52
Osaic Holdings
Scottsdale,
Arizona
| – | -$21K | -4,200 | Closed |
|
53
Rockefeller Capital Management
New York
| – | -$17K | -3,576 | Closed |
|
54
UBS Group
Zurich,
Switzerland
| – | -$11K | -2,270 | Closed |
|
|
CG
55
Cutler Group
San Francisco,
California
| – | -$5K | -1,100 | Closed |
|
|
TC
56
Truvestments Capital
Sarasota,
Florida
| – | -$3K | -637 | Closed |
|
57
Wells Fargo
San Francisco,
California
| – | -$2K | -521 | Closed |
|
|
CWA
58
Clearview Wealth Advisors
Salem,
Oregon
| – | -$1K | -300 | Closed |
|
59
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -200 | Closed |
|
|
APA
60
American Portfolios Advisors
Holbrook,
New York
| – | -$737 | -150 | Closed |
|
61
BNP Paribas Financial Markets
Paris,
France
| – | -$5 | -1 | Closed |
|
ADMS Hedge Fund Activity: Q4 2021 in Review
0 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2021, worth a combined $0 — down 100% from $148M a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of ADMS and 0 opened new positions — a net loss of 62 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Fidelity Investments, exiting entirely with an estimated $26.8M sold.
- 0 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2021, down from 63 in Q3 2021.
- Funds reported $0 of Adamas Pharmaceuticals stock for Q4 2021, down 100% quarter-over-quarter.
- 0 funds opened new Adamas Pharmaceuticals positions in Q4 2021 and 62 closed out, a net change of -62 holders.
- The largest Adamas Pharmaceuticals seller in Q4 2021 was Fidelity Investments, an estimated $26.8M sold.
Based on aggregated 13F filings for Q4 2021.